Answers are grounded in this paper and cite their sources.
Introduction: This review is focused on the methods used for biomarker discovery for Alzheimer’s disease (AD) in blood rather than on the nature of the biomarkers themselves.Areas covered: All biomarker discovery programs explicitly rely on contrasts in phenotype as a basis for defining differences. In this review, we explore the basis of contrasting choices as a function of the type of biomarker (genetic, protein, metabolite, non-coding RNA, or pathogenic epitope). We also provide an overview of the capacity to identify pathogenic epitopes with our new platform called Aptamarkers. It is suggested that a pre-existing hypothesis regarding the pathophysiology of the disease can act as a constraint to the development of biomarkers.Expert opinion: Limiting putative biomarkers to those that have a postulated role in the pathophysiology of disease imposes an unrealistic constraint on biomarker development. The understanding of Alzheimer’s disease would be accelerated by agnostic, non-hypothesis-based biomarker discovery methods. There is a need for more complex contrasts and more complex mathematical models.
No takes yet. Share an insight, caveat, or question.
Penner et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: